Shots:
- The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1,879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks.
- Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving A1C <7% (5.5%/88.9%/ 92.2% vs 81.1%); patients achieving A1C <5.7% (29.3% /44.7%/50.9% vs 19.7%) respectively
- The highest & lowest doses of therapy (15 & 5mg) led to an A1C reduction of 2.46 % & 2.09% with a reduction in body weight by 12.4 kg (13.1 %) & 7.8 kg (8.5%). Thus, all three doses of Tirzepatide showed a reduction in A1C and body weight
Click here to read full press release/ article | Ref: Lilly | Image: BioSpace
The post Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes first appeared on PharmaShots.
